Moleculin Biotech Inc (NASDAQ: MBRX)’s good-news rally had a short life.
The stock popped 55 percent Thursday after management announced a “breakthrough” discovery of a molecule capable of shutting down tumor activity and treating cancer.
But the stock took a 26-percent downturn Friday after Moleculin announced a $9 million offering and inspired profit-taking.
The series of events wasn’t unusual.
Companies, particularly pharmaceuticals and biotechs, commonly issue offerings off rallies to capitalize on the elevated prices and secure financing at a stronger valuation. Those funds can then advance research and development in yet unprofitable pipelines to set the stage for additional positive reports and more sustainable corresponding rallies.
However, the dilutive offering is poorly perceived by shareholders, whose holdings lose value as supply expands. Investors, then, tend to react by selling on the highs.
Moleculin saw fluctuation between $1.82 and $3.25 over the last few sessions, and shares stabilized around $2.08 Friday afternoon.
One Of The Creators Of The VXX Explains The Problem With Many Volatility Products
A Day Trader's Guide To Interpreting Volume
See more from Benzinga
- Deciphera Pharma Scores A Sell-Side Recommendation
- Height: Congressional Budget Deal A Boon For Private Prisons
- Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.